REFERENCES
- Dick D M, Foroud T. Candidate genes for alcohol dependence: a review of genetic evidence from human studies. Alcohol Clin Exp Res 2003; 27: 868–79, [PUBMED], [INFOTRIEVE], [CSA]
- Batra V, Patkar A A, Berrettini W H, Weinstein S P, Leone F T. The genetic determinants of smoking [Comment]. Chest 2003; 123: 1730–9, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet 2003; 118B: 48–54, [CROSSREF]
- Insel T R, Collins F S. Psychiatry in the genomics era. Am J Psychiatry 2003; 160: 616–20, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Merikangas K R, Risch N. Will the genomics revolution revolutionize psychiatry?. Am J Psychiatry 2003; 160: 625–35, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Reich T, Hinrichs A, Culverhouse R, Bierut L. Genetic studies of alcoholism and substance dependence. Am J Hum Genet 1999; 65: 599–605, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Diagnostic a nd. Statistical Manual of Mental Disorders 4th ed. American Psychiatric Association, Washington, DC 1994
- Merikangas K R, Avenevoli S. Implications of genetic epidemiology for the prevention of substance use disorders. Addict Behav 2000; 25: 807–20, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vanyukov M M, Tarter R E. Genetic studies of substance abuse. Drug Alcohol Depend 2000; 59: 101–23, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Uhl G R, Liu Q R, Naiman D. Substance abuse vulnerability loci: converging genome scanning data. Trends Genet 2002; 18: 420–5, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Uhl G R, Liu Q R, Walther D, Hess J, Naiman D. Polysubstance abuse–vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet 2001; 69: 1290–300, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Khoury M J, Beaty T. H., Cohen B. H. Fundamentals of genetic epidemiology. Oxford University Press, New York, Oxford 1993
- Merikangas K R, Stolar M, Stevens D E, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55: 973–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cadoret R J, Troughton E, O'Gorman T W, Heywood E. An adoption study of genetic and environmental factors in drug abuse. Arch Gen Psychiatry 1986; 43: 1131–6, [PUBMED], [INFOTRIEVE]
- Kendler K S, Heath A C, Neale M C, Kessler R C, Eaves L J. A population-based twin study of alcoholism in women. JAMA 1992; 268: 1877–82, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tsuang M T, Lyons M J, Meyer J M, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998; 55: 967–72, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kendler K S, Karkowski L M, Neale M C, Prescott C A. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000; 57: 261–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kendler K S, Jacobson K C, Prescott C A, Neale M C. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003; 160: 687–95, [PUBMED], [INFOTRIEVE], [CROSSREF]
- van den Bree M B, Johnson E O, Neale M C, Pickens R W. Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend 1998; 52: 231–41, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Howard L A, Sellers E M, Tyndale R F. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 2002; 3: 185–99, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Brzezinski M R, Spink B J, Dean R A, Berkman C E, Cashman J R, Bosron W F. Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab Dispos 1997; 25: 1089–96, [PUBMED], [INFOTRIEVE], [CSA]
- Coffman B L, Rios G R, King C D, Tephly T R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25: 1–4, [PUBMED], [INFOTRIEVE], [CSA]
- Salmon A Y, Goren Z, Avissar Y, Soreq H. Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin Exp Pharmacol Physiol 1999; 26: 596–600, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fisher M B, Vandenbranden M, Findlay K, et al. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 2000; 10: 727–39, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004; 12: 305–20, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Koob G F, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999; 22: 521–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tzschentke T M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001; 63: 241–320, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349: 975–86, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Koob G F, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97–129, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Emilien G, Maloteaux J M, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors—physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999; 84: 133–56, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bannon M J, Michelhaugh S K, Wang J, Sacchetti P. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 2001; 11: 449–55, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Miller G M, Madras B K. Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 2002; 7: 44–55, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Simeone T A, Donevan S D, Rho J M. Molecular biology and ontogeny of gamma-aminobutyric acid (GABA) receptors in the mammalian central nervous system. J Child Neurol 2003; 18: 39–48, discussion 49[PUBMED], [CSA]
- Yuzaki M. New insights into the structure and function of glutamate receptors: the orphan receptor delta2 reveals its family's secrets. Keio J Med 2003; 52: 92–9, [PUBMED], [INFOTRIEVE], [CSA]
- Burt D R. Reducing GABA receptors. Life Sci 2003; 73: 1741–58, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Goff D C, Coyle J T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367–77, [PUBMED], [CROSSREF]
- Gadea A, Lopez-Colome A M. Glial transporters for glutamate, glycine, and GABA: II. GABA transporters. J Neurosci Res 2001; 63: 461–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Meldrum B S, Akbar M T, Chapman A G. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res 1999; 36: 189–204, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Leshner A I. Understanding drug addiction: implications for treatment. Hosp Pract (Off Ed) 1996; 31: 47–54; 57–9
- Meltzer L T, Christoffersen C L, Serpa K A. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev 1997; 21: 511–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bodnar R J, Hadjimarkou M M. Endogenous opiates and behavior: 2001. Peptides 2002; 23: 2307–65, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Johnson S W, North R A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 1992; 12: 483–8, [PUBMED], [INFOTRIEVE]
- Inturrisi C E. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18: S3–13, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Iversen L. Cannabis and the brain. Brain 2003; 126: 1252–70, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 123–42, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fride E. Endocannabinoids in the central nervous system—an overview. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 221–33, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Onaivi E S, Leonard C M, Ishiguro H, et al. Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002; 66: 307–44, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Freund T F, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003; 83: 1017–66, [PUBMED], [INFOTRIEVE], [CSA]
- Nahas G, Harvey D J, Sutin K, Turndorf H, Cancro R. A molecular basis of the therapeutic and psychoactive properties of cannabis (delta9-tetrahydrocannabinol). Prog Neuro-Psychopharmacol Biol Psychiatry 2002; 26: 721–30, [CSA], [CROSSREF]
- Gardner E L. Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids 2002; 121: 267–90, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mechoulam R, Parker L. Cannabis and alcohol—a close friendship. Trends Pharmacol Sci 2003; 24: 266–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hohmann A G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002; 121: 173–90, [PUBMED], [INFOTRIEVE], [CSA]
- Gonzalez S, Cascio M G, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos J A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002; 954: 73–81, [PUBMED], [INFOTRIEVE]
- Solinas M, Panlilio L V, Antoniou K, Pappas L A, Goldberg S R. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-car- boxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 2003; 306: 93–102, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kroeze W K, Kristiansen K, Roth B L. Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem 2002; 2: 507–28, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Azmitia E C, Whitaker-Azmitia P M. Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry 1991; 52: 4–16, [PUBMED], [INFOTRIEVE]
- Inoue T, Kusumi I, Yoshioka M. Serotonin transporters. Curr Drug Targets C NS Neurol Disord 2002; 1: 519–29, [CROSSREF]
- Lesch K P, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–31, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Haughey H M, Fleckenstein A E, Metzger R R, Hanson G R. The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem 2000; 75: 1608–17, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Johnson B A, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000; 149: 327–44, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gottesman I I, Shields J. Genetic theorizing and schizophrenia. Br J Psychiatry 1973; 122: 15–30, [PUBMED], [INFOTRIEVE]
- Porjesz B, Begleiter H, Wang K, et al. Linkage and linkage disequilibrium mapping of ERP and EEG phenotypes. Biol Psychol 2002; 61: 229–48, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Armstrong S C, Cozza K L. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003; 44: 167–71, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Stone A N, Mackenzie P I, Galetin A, Houston J B, Miners J O. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 2003; 31: 1086–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- King C D, Rios G R, Assouline J A, Tephly T R. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys 1999; 365: 156–62, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Darvesh S, Hopkins D A, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Miners J O, McKinnon R A, Mackenzie P I. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; 181–182: 453–6, [CROSSREF]
- Hirota T, Ieiri I, Takane H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 2003; 31: 677–80, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sawyer M B, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73: 566–74, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tyndale R F, Droll K P, Sellers E M. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7: 375–9, [PUBMED], [INFOTRIEVE], [CSA]
- Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Disp 1998; 26: 818–21, [CSA]
- Moody D E, Alburges M E, Parker R J, Collins J M, Strong J M. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Disp 1997; 25: 1347–53, [CSA]
- Lamba J K, Lin Y S, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121–32, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hesselink D A, van Schaik R H, van der Heiden I P, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–54, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lawford B R, Young R M, Noble E P, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 2000; 96: 592–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Xu K, Lichtermann D, Lipsky R H, et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry 2004; 61: 597–606, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kotler M, Cohen H, Segman R, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry 1997; 2: 251–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Li T, Xu K, Deng H, et al. Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects. Mol Psychiatry 1997; 2: 413–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Duaux E, Gorwood P, Griffon N, et al. Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry 1998; 3: 333–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Galeeva A R, Gareeva A E, Iur'ev E B, Khusnutdinova E K. [VNTR polymorphisms of the serotonin transporter and dopamine transporter genes in male opiate addicts]. Mol Biol (Mosk) 2002; 36: 593–8, Russian[CSA]
- Bilder R M, Volavka J, Lachman H M, Grace A A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004; 29: 1943–61, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mannisto P T, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593–628, [PUBMED], [INFOTRIEVE]
- Horowitz R, Kotler M, Shufman E, et al. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 2000; 96: 599–603, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hoehe M R, Kopke K, Wendel B, et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 2000; 9: 2895–908, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mayer P, Hollt V. Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther 2001; 91: 167–77, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bond C, LaForge K S, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95: 9608–13, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Franke P, Wang T, Nothen M M, et al. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet 2001; 105: 114–9, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 1999; 4: 476–83, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schinka J A, Town T, Abdullah L, et al. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry 2002; 7: 224–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Luo X, Kranzler H R, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet 2003; 120B: 97–108, [CROSSREF]
- Mayer P, Rochlitz H, Rauch E, et al. Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 1997; 8: 2547–50, [PUBMED], [INFOTRIEVE], [CSA]
- Franke P, Nothen M M, Wang T, et al. Human delta-opioid receptor gene and susceptibility to heroin and alcohol dependence. Am J Med Genet 1999; 88: 462–4, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Comings D E, Blake H, Dietz G, et al. The proenkephalin gene (PENK) and opioid dependence. Neuroreport 1999; 10: 1133–5, [PUBMED], [INFOTRIEVE], [CSA]
- Li T, Liu X, Zhu Z H, et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000; 5: 128–30, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Warner A, Norman A B. Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther Drug Monit 2000; 22: 266–70, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ladona M G, Gonzalez M L, Rane A, Peter R M, de la Torre R. Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci 2000; 68: 431–43, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Persico A M, Bird G, Gabbay F H, Uhl G R. D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry 1996; 40: 776–84, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Comings D E, Gonzalez N, Wu S, et al. Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence. Mol Psychiatry 1999; 4: 484–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gelernter J, Kranzler H, Satel S L. No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. Biol Psychiatry 1999; 45: 340–5, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Freimer M, Kranzler H, Satel S, et al. No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. Addict Biol 1996; 1: 281–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cubells J F, Kranzler H R, McCance-Katz E, et al. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry 2000; 5: 56–63, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cigler T, LaForge K S, McHugh P F, Kapadia S U, Leal S M, Kreek M J. Novel and previously reported single-nucleotide polymorphisms in the human 5-HT(1B) receptor gene: no association with cocaine or alcohol abuse or dependence. Am J Med Genet 2001; 105: 489–97, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Patkar A A, Berrettini W H, Hoehe M, et al. No association between polymorphisms in the serotonin transporter gene and susceptibility to cocaine dependence among African-American individuals. Psychiatr Genet 2002; 12: 161–4, [PUBMED], [INFOTRIEVE], [CSA]
- Chen A C, LaForge K S, Ho A, et al. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet 2002; 114: 429–35, [PUBMED], [INFOTRIEVE]
- Comings D E, Muhleman D, Gade R, et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 1997; 2: 161–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Covault J, Gelernter J, Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry 2001; 6: 501–2, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Freimer N, Sabatti C. The use of pedigree, sib-pair and association studies of common diseases for genetic mapping and epidemiology. Nat Genet 2004; 36: 1045–51, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bierut L J, Dinwiddie S H, Begleiter H, et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry 1998; 55: 982–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Marchini J, Donnelly P, Cardon L R. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet 2005; 37: 413–7, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Veverka K A, Johnson K L, Mays D C, Lipsky J J, Naylor S. Inhibition of aldehyde dehydrogenase by disulfiram and its metabolite methyl diethylthiocarbamoyl-sulfoxide. Biochem Pharmacol 1997; 53: 511–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nich C, McCance-Katz E F, Petrakis I L, Cubells J F, Rounsaville B J, Carroll K M. Sex differences in cocaine-dependent individuals' response to disulfiram treatment. Addict Behav 2004; 29: 1123–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Carroll K M, Fenton L R, Ball S A, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 264–72, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McCance-Katz E F, Kosten T R, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998; 52: 27–39, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]